Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Glioblastoma 49Breast Neoplasms 49Prostatic Neoplasms 47Carcinoma, Non-Small-Cell Lung 47Squamous Cell Carcinoma of Head and Neck 37Lung Neoplasms 29Head and Neck Neoplasms 26Glioma 22Rectal Neoplasms 21Sarcoma 20Neoplasms 20Brain Neoplasms 20Oropharyngeal Neoplasms 16Esophageal Neoplasms 15Uterine Cervical Neoplasms 14Neoplasm Metastasis 14Astrocytoma 13Triple Negative Breast Neoplasms 12Esophageal Squamous Cell Carcinoma 12Carcinoma, Hepatocellular 12Pancreatic Neoplasms 11Melanoma 11Gliosarcoma 10Colorectal Neoplasms 10Stomach Neoplasms 9Small Cell Lung Carcinoma 9Lymphoma 9Hodgkin Disease 9Carcinoma, Squamous Cell 9Urinary Bladder Neoplasms 8

Interventions

Cyclophosphamide 22Dexamethasone 15Cytarabine 14venetoclax 13Vincristine 13Methotrexate 10Etoposide 10Prednisone 9Doxorubicin 9Calcium Dobesilate 9prednylidene 8dexamethasone acetate 8dexamethasone 21-phosphate 8deltacortene 8auricularum 8merphos 7Specimen Handling 7pegaspargase 6fludarabine phosphate 6daratumumab 6calaspargase pegol 6Mercaptopurine 6Granulocyte Colony-Stimulating Factor 6fludarabine 5Stem Cell Transplantation 5Filgrastim 5Daunorubicin 5Bortezomib 5Biopsy 5Asparaginase 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Radiotherapy × 1 year × Clear all
NCT02112916 2026-06-03

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
847 enrolled 19 charts
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡